Genetically Engineered Biomaterials: Using Science to Mimic Nature

June 27, 2019 | 18 views

Biomaterials are naturally occurring materials, derived either from plants or animals. Due to their superior properties, these materials find uses in many industries. Synthetic biologists are constantly researching ways to mimic these materials as well as ways to improve on them. In this article, we will discuss why it is important to develop synthetic versions of nature’s building blocks, and about the companies that have succeeded in doing so. Finally, we will learn how CRISPR is contributing to the world of biomaterials.

Spotlight

Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals, located near the Houston Medical Center, is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. We are developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT) and CAR T cell therapy.

OTHER ARTICLES
MEDTECH

2022 U.S. Market Research Report with COVID-19 Forecasts2

Article | July 12, 2022

The global biotechnology market is expected to grow at a compound annual growth rate (CAGR) of 13.9 percent from 2022 to 2030, with a value estimated at USD 1,023.92 billion in 2021. The market is being propelled by strong government support in the form of initiatives aimed at modernizing the regulatory framework, improving approval processes and reimbursement policies, and standardizing clinical studies. The growing presence of personalized medicine and an increasing number of orphan drug formulations are opening up new avenues for biotechnology applications and driving the influx of emerging and innovative biotechnology companies, which is driving market revenue even further. The 2022 Biotech Research and Development Market Research Report is one of the most comprehensive and in-depth assessments of the industry in the United States, containing over 100 data sets spanning the years 2013 to 2026. This Kentley Insights report contains historical and forecasted market size, product lines, profitability, financial ratios, BCG matrix, state statistics, operating expense details, organizational breakdown, consolidation analysis, employee productivity, price inflation, pay bands for the top 20 industry jobs, trend analysis and forecasts on companies, locations, employees, payroll, and much more. Companies in the Biotech Research and Development industry are primarily engaged in biotechnology research and experimental development. Biotechnology research and development entails the investigation of the use of microorganisms and cellular and bimolecular processes to create or modify living or non-living materials. This biotechnology research and development may result in the development of new biotechnology processes or prototypes of new or genetically altered products that can be replicated, used, or implemented by various industries. This report was created using the findings of extensive business surveys and econometrics. The professionals follow reports with accurate and apt information on market sizing, benchmarking, strategic planning, due diligence, cost-cutting, planning, understanding industry dynamics, forecasting, streamlining, gap analysis, and other ana

Read More
MEDICAL

Biotech in 2022

Article | June 22, 2022

The robust global channel of more than, 800 gene and cell curatives presently in trials will produce clinical readouts in 2022, revealing what lies ahead for advanced curatives. The impact will be felt in 2022, no matter how you slice it. Eventually, how well industry and non-supervisory bodies unite to produce new frameworks for advanced therapies will shape the year 2022 and further. Pacific Northwest talent will continue to contribute to the advancement of gene and cell curatives in both the short and long term, thanks to its deep pool of ground-breaking scientific developers, entrepreneurial directorial leadership, largely skilled translational scientists, and endured bio manufacturing technicians. We may see continued on-life science fund withdrawal from biotech in 2021, but this can be anticipated as a strong comeback in 2022 by biotech industry, backed by deep-pocketed life science investors who are committed to this sector. A similar investment, combined with pharma's cash-heavy coffers, can result in increased junction and acquisition activity, which will be a challenge for some but an occasion for others. Over the last five years, investment interest in Seattle and the Pacific Northwest has grown exponentially, from Vancouver, British Columbia, to Oregon. The region's explosive portfolio of new biotech companies, innovated out of academic centres, demonstrates the region's growing recognition of scientific invention. This created a belief that continued, especially because Seattle's start-ups and biotech enterprises are delivering on their pledge of clinical and patient impact. Talent and staffing will continue to be difficult to find. It's a CEO's market, but many of these funds' return, and are not rising in proportion to the exorbitant prices they're paying to enter deals. This schism has become particularly pronounced in 2021. Hence, everyone in biotech is concerned about reclamation and retention.

Read More
MEDTECH

Next-Gen Genetics Cancer Therapies Creating Investment Prospects

Article | July 16, 2022

Genetic therapeutics such as genetic engineering and gene therapy are increasingly emerging as one of the most influential and transformed biotechnological solutions around the globe in recent times. These genetic solutions are being assessed across various medical domains, including cancer treatment, neurology, oncology, and ophthalmology. Citing the trend, the genetics industry is estimated to experience a tsunami of approvals, with over 1,000 cell and gene therapy clinical trials currently underway and over 900 companies worldwide focusing on these cutting-edge therapies. Growing Cancer Encourages Advancements in Genetic Technologies With the surging cases of cancers such as leukemias, carcinomas, lymphomas, and others, patients worldwide are increasing their spending on adopting novel therapeutic solutions for non-recurring treatment of the disease, such as gene therapy, genetic engineering, T-cell therapy, and gene editing. As per a study by the Fight Cancer Organization, spending on the treatment of cancer increased to $200.7 billion, and the amount is anticipated to exceed $245 billion by the end of 2030. Growing revenue prospects are encouraging biotechnology and biopharmaceutical companies to develop novel genetic solutions for cancer treatment. For instance, Bristol-Myers Squibb K.K., a Japanese pharmaceutical company, introduced a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy, Abecma, for the treatment of relapsed or refractory (R/R) multiple myeloma in 2022. Amid a New Market: Genetics Will Attract Massive Investments Despite several developments and technological advancements, genetics is still considered to be in a nascent stage, providing significant prospects for growth to the companies that are already operating in the domain. Genetics solutions such as gene therapies, gene editing, and T-cell immunotherapy are emerging as highly active treatments across various medical fields, resulting in increasing research and development activities across the domain, drawing significant attention from investors. Given the potential of genetic treatments and the focus on finding new ways to treat cancer and other related diseases, it's easy to understand why companies are investing in the domain. For instance, Pfizer has recently announced an investment of around $800 million to construct development facilities supporting gene therapy manufacturing from initial preclinical research through final commercial-scale production. Due to these advancements, cell and gene therapies are forecast to grow from $4 billion annually to more than $45 billion, exhibiting growth at a 63% CAGR. The Future of Genetics Though there is a significant rise in advancement in genetic technologies and developments, the number of approved genetic treatments remains extremely small. However, with gene transfer and CRISPR solutions emerging as new modalities for cancer treatment, the start-up companies will attract a growing amount and proportion of private and public investments. This is expected present a tremendous opportunity for biopharma and biotechnology investors to help fund and benefit from the medical industry's shift from traditional treatments to cutting-edge genetic therapeutics in the coming years.

Read More
MEDICAL

Advancement in Genomics Accelerating its Penetration into Precision Health

Article | June 22, 2022

Genomics is an interdisciplinary field of biology emphasizing the structure, editing, evolution, function, and mapping of genomes. It is creating deeper inroads across the precision health domain with the increasing introduction of advanced technologies such as quantum simulation, next-generation sequencing (NGS), and precise genome manipulation. As precision health focuses on providing the proper intervention to the right patient at the right time, genomics increasingly finds applications in human and pathogen genome sequencing in clinical and research spaces. Rising Hereditary Diseases Burden Paving the Way for Genomics in Precision Health In the last few years, a significant surge in the prevalence of diseases and ailments such as diabetes, obesity, baldness, and others has been witnessed across the globe. A history of family members with chronic diseases, such as cancer, diabetes, high blood pressure, hearing issues, and heart disease, can sometimes continue into the next generation. Hence, the study of genes is extensively being conducted for predicting health risks and early treatment of these diseases. It also finds use in CRISPR-based diagnostics and the preparation of precision medication for the individual. In addition, ongoing advancements in genomics are making it possible to identify different genetic traits that persuade people to more widespread diseases and health problems. The Emergence of Genomics Improves Disease Understanding Genomics refers to the study of the complete genetic makeup of a cell or organism. Increasing scientific research in the area substantially contributes to increasing knowledge about the human genome and assists in improving the ability to understand disease etiology, risk, diagnosis, treatment, and prevention. On account of these improvements, innovative genomic technologies and tools are being developed to enable better precision health not only for the individual but for various regional populations as well. The Way Forward With growing preference for personalized medicine and an increasing need for more accurate pathogen detection and diagnostics, genomics is gaining huge popularity across the precision health domain. Also, increasing research activities for developing novel high-precision therapeutics and rising importance of gene study in the prevention, diagnosis, and management of infectious and genetic diseases will further pave the way for genomics in the forthcoming years.

Read More

Spotlight

Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals, located near the Houston Medical Center, is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. We are developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT) and CAR T cell therapy.

Related News

AquaBounty considers labelling genetically modified salmon

CBC.CA | April 16, 2019

The U.S.-based company that's about to start the commercial production of genetically modified salmon in P.E.I. says it's considering labelling the product as such. However, it's not clear what exactly AquaBounty Technologies intends to tell consumers about the fish, which are modified with a growth hormone gene to make them grow faster. "We are considering our labelling options and working with potential customers to determine the appropriate approach," a spokesperson for AquaBounty said in a statement sent to CBC News. The genetically modified salmon, produced in indoor tanks in Rollo Bay, P.E.I., will become the first genetically engineered food animal to be sold in Canadian grocery stores. Environment Canada and Health Canada have given their approval, but it's up to the latter to determine whether products require labelling. "Health Canada requires labelling for food products where clear, scientifically established health risks or significant nutritional changes have been identified that can be mitigated through labelling," said spokesperson Maryse Durette. 'Safe and nutritious,' Health Canada says After a four-year study, the federal agency has determined the genetically modified salmon to be "safe and nutritious" and therefore no labelling is required. AquaBounty's most recent statement on labelling is news to Sylvain Charlebois, a Dalhousie University professor in food distribution and policy. "I did encourage AquaBounty to reconsider its policy around transparency and risk communication," he said Sunday on CBC Radio's Maritime Connection. "It is a pleasant surprise to me because I do think that the industry is starting to realize how important it is to connect with the public more so than ever before to get that social licence." AquaBounty Technologies is planning to grow 250 tonnes of its AquAdvantage salmon in Rollo Bay. The fish will be on the market in late 2020.

Read More

AquaBounty considers labelling genetically modified salmon

CBC.CA | April 16, 2019

The U.S.-based company that's about to start the commercial production of genetically modified salmon in P.E.I. says it's considering labelling the product as such. However, it's not clear what exactly AquaBounty Technologies intends to tell consumers about the fish, which are modified with a growth hormone gene to make them grow faster. "We are considering our labelling options and working with potential customers to determine the appropriate approach," a spokesperson for AquaBounty said in a statement sent to CBC News. The genetically modified salmon, produced in indoor tanks in Rollo Bay, P.E.I., will become the first genetically engineered food animal to be sold in Canadian grocery stores. Environment Canada and Health Canada have given their approval, but it's up to the latter to determine whether products require labelling. "Health Canada requires labelling for food products where clear, scientifically established health risks or significant nutritional changes have been identified that can be mitigated through labelling," said spokesperson Maryse Durette. 'Safe and nutritious,' Health Canada says After a four-year study, the federal agency has determined the genetically modified salmon to be "safe and nutritious" and therefore no labelling is required. AquaBounty's most recent statement on labelling is news to Sylvain Charlebois, a Dalhousie University professor in food distribution and policy. "I did encourage AquaBounty to reconsider its policy around transparency and risk communication," he said Sunday on CBC Radio's Maritime Connection. "It is a pleasant surprise to me because I do think that the industry is starting to realize how important it is to connect with the public more so than ever before to get that social licence." AquaBounty Technologies is planning to grow 250 tonnes of its AquAdvantage salmon in Rollo Bay. The fish will be on the market in late 2020.

Read More

Events